Fromilid coated tablets 250 mg. №14

Description

FROMILID 250 mg COMPOSITION
active substance: clarithromycin

1 tablet contains 250 mg or 500 mg clarithromycin

auxiliary substances: corn starch, microcrystalline cellulose, colloidal silicon dioxide, corn starch, potassium polacrilin, talc, magnesium stearate, propylene glycol, iron dye yellow oxide (E172), titanium dioxide (E 171).

FROMILID 250 mg DOSAGE FORM
Film-coated tablets.

FROMILID 250 mg MAIN PHYSICAL AND CHEMICAL PROPERTIES:
oval convex tablets of slightly brownish-yellow color, film-coated.

PHARMACOLOGICAL GROUP
Antimicrobial agents for systemic use. Macrolides, lincosamides and streptogramins. Clarithromycin. ATX code J01F A09.

PHARMACOLOGICAL PROPERTIES

Pharmacological.

Clarithromycin, a semi-synthetic antibiotic of the macrolide group, interacts with the 50S ribosomal subunit of bacteria, thus inhibiting protein synthesis.

Basically, it has a bacteriostatic, and in some cases also a bactericidal effect (against Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhal).

The following microorganisms are sensitive to clarithromycin: Mycoplasma pneumoniae, Legionella pheumophila, Chlamydia trachomatis and C. pneumoniae, Ureaplasma urealyticum gram-positive microorganisms (streptococci and staphylococci, Listeria monocytogenes, H. i. pertussis, Neisseria gonorrhoeae i N. meningitidis, Borrelia burgdorferi, Pasteurella multocida, Campylobacter spp. and Helicobacter pylori), some anaerobes (Eubacterium spp., Peptococcus spp., Beptostreptococcus spp., Beptostreptococcus melanosus, Peptostreptococcus spp. all mycobacteria except M. tuberculosis.

INDICATIONS
Infections caused by microorganisms sensitive to clarithromycin.

Lower respiratory tract infections (bronchitis, acute lobar pneumonia and primary Antipova pneumonia).
Upper respiratory tract infections, i.e. nasopharynx (tonsillitis, pharyngitis), and sinus infections.
Skin and soft tissue infections (impetigo, folliculitis, erysipeloid, furunculosis, infected wounds).
Guests and chronic odontonenny infections.
Disseminated or localized mycobacterial infections caused by Mycobacterium avium or Mycobacterium intracellulare. Localized infections caused by Mycobacterium chelonae, Mycobacterium fortuitum, or Mycobacterium kansasii.
Eradication of H. pylori in patients with duodenal ulcer with inhibition of hydrochloric acid secretion (the activity of clarithromycin against H. pylori is higher at neutral pH than at acidic pH).
Contraindications
Hypersensitivity to clarithromycin or other macrolide antibiotics or to any of the drug’s components.